SLAMF6 and B-cell chronic lymphocytic leukemia: First, Yigit et al. demonstrated that anti-SLAMF6 treatment improved in vivo T cell activity against chronic lymphocytic leukemia and melanoma by opposing the increase in exhaustion-related receptors, such as PD-1 [39].